{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:49:50Z","timestamp":1790272190956,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["11-14-08"],"award-info":[{"award-number":["11-14-08"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tenax Therapeutics"},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["RP-2015-06-018"],"award-info":[{"award-number":["RP-2015-06-018"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00134-019-05731-w","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T02:02:41Z","timestamp":1566180161000},"page":"1392-1400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial"],"prefix":"10.1007","volume":"45","author":[{"given":"David B.","family":"Antcliffe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Santhakumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M. L.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie K.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Al-Beidh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"O\u2019Dea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin D.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervyn","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexina J.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-547X","authenticated-orcid":false,"given":"Anthony C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"5731_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304\u2013377. \n                    https:\/\/doi.org\/10.1007\/s00134-017-4683-6","journal-title":"Intensive Care Med"},{"key":"5731_CR2","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1097\/CCM.0b013e318174db05","volume":"36","author":"A Vieillard-Baron","year":"2008","unstructured":"Vieillard-Baron A, Caille V, Charron C et al (2008) Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 36:1701\u20131706. \n                    https:\/\/doi.org\/10.1097\/CCM.0b013e318174db05","journal-title":"Crit Care Med"},{"key":"5731_CR3","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1378\/chest.116.5.1354","volume":"116","author":"F Jardin","year":"1999","unstructured":"Jardin F, Fourme T, Page B et al (1999) Persistent preload defect in severe sepsis despite fluid loading. Chest 116:1354\u20131359. \n                    https:\/\/doi.org\/10.1378\/chest.116.5.1354","journal-title":"Chest"},{"key":"5731_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIRCOUTCOMES.117.004040","volume":"11","author":"JF Frencken","year":"2018","unstructured":"Frencken JF, Donker DW, Spitoni C et al (2018) Myocardial injury in patients with sepsis and its association with long-term outcome. Circ Cardiovasc Qual Outcomes 11:1\u20139. \n                    https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.117.004040","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"5731_CR5","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1007\/s00134-016-4503-4","volume":"42","author":"A Aneman","year":"2016","unstructured":"Aneman A, Vieillard-Baron A (2016) Cardiac dysfunction in sepsis. Intensive Care Med 42:2073\u20132076. \n                    https:\/\/doi.org\/10.1007\/s00134-016-4503-4","journal-title":"Intensive Care Med"},{"key":"5731_CR6","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s00134-012-2531-2","volume":"38","author":"CA Schmittinger","year":"2012","unstructured":"Schmittinger CA, Torgersen C, Luckner G et al (2012) Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med 38:950\u2013958. \n                    https:\/\/doi.org\/10.1007\/s00134-012-2531-2","journal-title":"Intensive Care Med"},{"key":"5731_CR7","doi-asserted-by":"publisher","first-page":"R181","DOI":"10.1186\/cc8167","volume":"13","author":"MW D\u00fcnser","year":"2009","unstructured":"D\u00fcnser MW, Ruokonen E, Pettil\u00e4 V et al (2009) Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 13:R181. \n                    https:\/\/doi.org\/10.1186\/cc8167","journal-title":"Crit Care"},{"key":"5731_CR8","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00134-016-4249-z","volume":"42","author":"DT Andreis","year":"2016","unstructured":"Andreis DT, Singer M (2016) Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. Intensive Care Med 42:1387\u20131397. \n                    https:\/\/doi.org\/10.1007\/s00134-016-4249-z","journal-title":"Intensive Care Med"},{"key":"5731_CR9","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1056\/NEJMoa1609409","volume":"375","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Perkins GD, Singer M et al (2016) Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 375:1638\u20131648. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1609409","journal-title":"N Engl J Med"},{"key":"5731_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0009-9236(97)90139-9","volume":"61","author":"H Ukkonen","year":"1997","unstructured":"Ukkonen H, Saraste M, Akkila J et al (1997) Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 61:596\u2013607. \n                    https:\/\/doi.org\/10.1016\/S0009-9236(97)90139-9","journal-title":"Clin Pharmacol Ther"},{"key":"5731_CR11","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1097\/CCM.0000000000001269","volume":"43","author":"Q Wang","year":"2015","unstructured":"Wang Q, Yokoo H, Takashina M et al (2015) Anti-inflammatory profile of levosimendan in cecal ligation-induced septic mice and in lipopolysaccharide-stimulated macrophages. Crit Care Med 43:e508\u2013e520. \n                    https:\/\/doi.org\/10.1097\/CCM.0000000000001269","journal-title":"Crit Care Med"},{"key":"5731_CR12","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/cc10307","volume":"15","author":"J Hasslacher","year":"2011","unstructured":"Hasslacher J, Bijuklic K, Bertocchi C et al (2011) Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Crit Care 15:R166. \n                    https:\/\/doi.org\/10.1186\/cc10307","journal-title":"Crit Care"},{"key":"5731_CR13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.amjcard.2004.01.073","volume":"93","author":"JT Parissis","year":"2004","unstructured":"Parissis JT, Adamopoulos S, Antoniades C et al (2004) Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93:1309\u20131312. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2004.01.073","journal-title":"Am J Cardiol"},{"key":"5731_CR14","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1056\/nejmc1616632","volume":"376","author":"H Groesdonk","year":"2017","unstructured":"Groesdonk H, Sander M, Heringlake M (2017) Levosimendan in sepsis. N Engl J Med 376:798\u2013800. \n                    https:\/\/doi.org\/10.1056\/nejmc1616632","journal-title":"N Engl J Med"},{"key":"5731_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/1745-6215-15-199","volume":"15","author":"RML Orme","year":"2014","unstructured":"Orme RML, Perkins GD, McAuley DF et al (2014) An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial. Trials 15:199. \n                    https:\/\/doi.org\/10.1186\/1745-6215-15-199","journal-title":"Trials"},{"key":"5731_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/eme05060","volume":"5","author":"AC Gordon","year":"2018","unstructured":"Gordon AC, Santhakumaran S, Al-Beidh F et al (2018) Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT. Eff Mech Eval 5:1\u201394. \n                    https:\/\/doi.org\/10.3310\/eme05060","journal-title":"Eff Mech Eval"},{"key":"5731_CR17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/CCM.0000000000000107","volume":"42","author":"G Landesberg","year":"2014","unstructured":"Landesberg G, Jaffe AS, Gilon D et al (2014) Troponin elevation in severe sepsis and septic shock: the role of left ventricular diastolic dysfunction and right ventricular dilatation. Crit Care Med 42:790\u2013800. \n                    https:\/\/doi.org\/10.1097\/CCM.0000000000000107","journal-title":"Crit Care Med"},{"key":"5731_CR18","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/01.ccm.0000114827.93410.d8","volume":"32","author":"J Charpentier","year":"2004","unstructured":"Charpentier J, Luyt C-E, Fulla Y et al (2004) Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 32:660\u2013665. \n                    https:\/\/doi.org\/10.1097\/01.ccm.0000114827.93410.d8","journal-title":"Crit Care Med"},{"key":"5731_CR19","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1097\/CCM.0b013e31818b9153","volume":"36","author":"F Post","year":"2008","unstructured":"Post F, Weilemann LS, Messow C-M et al (2008) B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients. Crit Care Med 36:3030\u20133037. \n                    https:\/\/doi.org\/10.1097\/CCM.0b013e31818b9153","journal-title":"Crit Care Med"},{"key":"5731_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1164\/rccm.201603-0645OC","volume":"195","author":"KR Famous","year":"2017","unstructured":"Famous KR, Delucchi K, Ware LB et al (2017) Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 195:331\u2013338. \n                    https:\/\/doi.org\/10.1164\/rccm.201603-0645OC","journal-title":"Am J Respir Crit Care Med"},{"key":"5731_CR21","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1001\/jama.286.14.1754","volume":"286","author":"FL Ferreira","year":"2001","unstructured":"Ferreira FL, Bota DP, Bross A et al (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754\u20131758","journal-title":"JAMA"},{"key":"5731_CR22","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1097\/CCM.0000000000000212","volume":"42","author":"AC Gordon","year":"2014","unstructured":"Gordon AC, Mason AJ, Perkins GD et al (2014) The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med 42:1325\u20131333. \n                    https:\/\/doi.org\/10.1097\/CCM.0000000000000212","journal-title":"Crit Care Med"},{"key":"5731_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/jama.2016.10485","volume":"316","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Mason AJ, Thirunavukkarasu N et al (2016) Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316:509\u2013518. \n                    https:\/\/doi.org\/10.1001\/jama.2016.10485","journal-title":"JAMA"},{"key":"5731_CR24","doi-asserted-by":"publisher","first-page":"c4130","DOI":"10.1136\/bmj.c4130","volume":"341","author":"A Al-Mohammad","year":"2010","unstructured":"Al-Mohammad A, Mant J, Laramee P et al (2010) Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance. BMJ 341:c4130. \n                    https:\/\/doi.org\/10.1136\/bmj.c4130","journal-title":"BMJ"},{"key":"5731_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/00949650215733","volume":"73","author":"MJ Anderson","year":"2003","unstructured":"Anderson MJ, Ter Braak CJF (2003) Permutation tests for multi-factorial analysis of variance. J Stat Comput Simul 73:85\u2013113. \n                    https:\/\/doi.org\/10.1080\/00949650215733","journal-title":"J Stat Comput Simul"},{"key":"5731_CR26","unstructured":"R Core Team (2015) R: a language and environment for statistical computing. R Foundation for Statistical Computing"},{"key":"5731_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1008929526011","volume":"10","author":"DJ Lunn","year":"2000","unstructured":"Lunn DJ, Thomas A, Best N, Spiegelhalter D (2000) WinBUGS - A Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 10:325\u2013337. \n                    https:\/\/doi.org\/10.1023\/A:1008929526011","journal-title":"Stat Comput"},{"key":"5731_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/BF01701475","volume":"21","author":"J Boldt","year":"1995","unstructured":"Boldt J, Menges T, Kuhn D et al (1995) Alterations in circulating vasoactive substances in the critically ill\u2014a comparison between survivors and non-survivors. Intensive Care Med 21:218\u2013225. \n                    https:\/\/doi.org\/10.1007\/BF01701475","journal-title":"Intensive Care Med"},{"key":"5731_CR29","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jama.2013.278477","volume":"310","author":"A Morelli","year":"2013","unstructured":"Morelli A, Ertmer C, Westphal M et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock. JAMA 310:1683\u20131691. \n                    https:\/\/doi.org\/10.1001\/jama.2013.278477","journal-title":"JAMA"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05731-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00134-019-05731-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05731-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T19:12:49Z","timestamp":1597691569000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00134-019-05731-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["5731"],"URL":"https:\/\/doi.org\/10.1007\/s00134-019-05731-w","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"24 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The views expressed in this article are those of the authors and not necessarily those of the MRC, the National Health Service (NHS), the NIHR, or the Department of Health. ACG reports receiving speaker fees from Amomed Pharma, consulting fees from Ferring Pharmaceuticals, Baxter Healthcare, Bristol-Myers Squibb and GlaxoSmithKline and grant support from HCA International, all paid to his institution; GDP receives fees for serving on an advisory board for GlaxoSmithKline; DFM receives consulting fees from Peptinnovate, Sobi, Bayer, Boehringer Ingelheim, and GlaxoSmithKline and fees to his institution from GlaxoSmithKline for participating in a clinical trial, and being named on a patent related to a new treatment for the acute respiratory distress syndrome (Canada, US, Australia, and European Union patent no., WO 2011073685, issued to Queen\u2019s University Belfast). MS receives consulting fees and grant support from Apollo Therapeutics, Baxter, Deltex Medical, Defence Science and Technology Laboratory, GE Healthcare, Medical Technology Associates II and New Beta Innovation all paid to his institution, and heads a Data Safety Monitoring Board on behalf of Shionogi. No other potential conflict of interest relevant to this article was reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}